Medical Devices

HTA plays an essential role in decision making and informing policy on the use of medical devices as a part of its broader scope for all technologies, as well as the efficient use of resources in health care. The mission of the MDIG is to promote and develop the interdisciplinary and multi-stakeholder assessments of medical devices and value-based healthcare in a consistent and comprehensive manner.

HTAI Default logo

Overview

HTA plays an essential role in decision making and informing policy on the use of medical devices as a part of its broader scope for all technologies, as well as the efficient use of resources in health care. The mission of the MDIG is to promote and develop the interdisciplinary and multi-stakeholder assessments of medical devices and value-based healthcare in a consistent and comprehensive manner.

Organization Information

Co-Chairs: Richard Charter, Switzerland | Anastasia, Chalkidou, United Kingdom
Technical Officer: Jarno Suominen, Finland

Join IG

Contact our Technical Officer to find out how to become part of this interest group.

Jarno Suominen
to.medicaldevices@htai.org

Aims and Objectives

The MD IG has the goal to produce relevant, objective research to inform and improve policy making that is intended to improve population health. The IG will advance the dialogue on Medical Device HTA methods and evidence based policy making. This will reflect all stakeholder groups and ensure the unique role of HTAi is considered in policy discussion.

Those interested in this IG will:

  • Contribute to ensure best practices in the HTA of medical technologies are shared and rigorously evaluated in a manner that considers the nuances of the medical device space.
  • Ensure the implementation of HTA is discussed and advanced to key policy makers.
  • Ensure all stakeholders are engaged and given a place to provide feedback on the strengths, weaknesses, challenges and opportunities of introducing Medical Device innovation into healthcare systems under the responsibility of increasing patient outcomes and lowering system costs.
  • Rigorously seek to include new stakeholders for dialogue, most notably payer and procurement thought leaders who are crucial actors in the implementation of medical device and value based healthcare assessments.

Webinars

View the Recording

HTA and Value-Based Healthcare: Methods
March 4, 2021 9:00 a.m. MST

Panelists:

  • Richard Charter, Vice-President, Alira Health
  • Iga Lipska, Research Project Manager at National Health Fund
  • Anastasia Chalkidou, Associate Director and Senior Research Fellow in HTA
  • Joseph Casey, Professor, Director of Partnerships and Programme

Session Details
This session will discuss the methodological differences between HTA and Value-Based Healthcare and how they can be applied to Medical Devices. The aim is to provide participants with a comprehensive understanding of how HTA and VBHC methods can be used in practice. It will further the goals and mission of the Medical Devices Interest Group, including advancing the dialogue on Medical Device HTA methods and evidence-based policy-making to develop the way we evaluate a rapidly evolving technology sector.

View the Recording

HTA and Value-Based Healthcare: Methods
March 25, 2021 8:00 a.m. MST

Panelists:

  • Richard Charter, Vice-President, Alira Health
  • Andrea Rappagliosi, Vice President Market Access, Public Affairs & Communication EMEA, Canada and LATAM Edwards Lifesciences
  • Joseph Casey, Professor, Director of Partnerships and Programme

Session Details
This session will build on the methods discussed in the first session through a series of case studies. Using real-life experiences, the speakers will distinguish the roles of HTA and Value-Based Healthcare in the evaluation and implementation of medical technologies and discuss value-based access programs (managed entry agreements). This session aims to give participants an understanding of how to implement the different methods in practice and will discuss how they complement each other in a rapidly evolving MedTech landscape.